- Home
- PSBD vs ELYM Comparison
PSBD vs ELYM Comparison
Compare PSBD & ELYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSBD
- ELYM
- Stock Information
- Founded
- PSBD 2009
- ELYM 2018
- Country
- PSBD United States
- ELYM United States
- Employees
- PSBD N/A
- ELYM N/A
- Industry
- PSBD
- ELYM Biotechnology: Pharmaceutical Preparations
- Sector
- PSBD
- ELYM Health Care
- Exchange
- PSBD Nasdaq
- ELYM Nasdaq
- Market Cap
- PSBD 531.4M
- ELYM 440.8M
- IPO Year
- PSBD 2024
- ELYM 2021
- Fundamental
- Price
- PSBD $16.39
- ELYM $7.39
- Analyst Decision
- PSBD Buy
- ELYM
- Analyst Count
- PSBD 7
- ELYM 0
- Target Price
- PSBD $16.93
- ELYM N/A
- AVG Volume (30 Days)
- PSBD 18.1K
- ELYM 260.6K
- Earning Date
- PSBD 08-08-2024
- ELYM 08-14-2024
- Dividend Yield
- PSBD 10.25%
- ELYM N/A
- EPS Growth
- PSBD N/A
- ELYM N/A
- EPS
- PSBD N/A
- ELYM N/A
- Revenue
- PSBD N/A
- ELYM N/A
- Revenue This Year
- PSBD N/A
- ELYM N/A
- Revenue Next Year
- PSBD N/A
- ELYM N/A
- P/E Ratio
- PSBD N/A
- ELYM N/A
- Revenue Growth
- PSBD N/A
- ELYM N/A
- 52 Week Low
- PSBD $15.27
- ELYM $2.35
- 52 Week High
- PSBD $17.12
- ELYM $11.55
- Technical
- Relative Strength Index (RSI)
- PSBD N/A
- ELYM 57.40
- Support Level
- PSBD N/A
- ELYM $5.65
- Resistance Level
- PSBD N/A
- ELYM $7.89
- Average True Range (ATR)
- PSBD 0.00
- ELYM 0.50
- MACD
- PSBD 0.00
- ELYM 0.20
- Stochastic Oscillator
- PSBD 0.00
- ELYM 77.68
About PSBD Palmer Square Capital BDC Inc.
Palmer Square Capital BDC Inc is a financial services company that lends to and invests in corporate debt securities of companies, including small to large private U.S. companies. Their investment objective is to maximize total return, comprised of current income and capital appreciation.
About ELYM Eliem Therapeutics Inc
Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Its main drug candidate is ETX-155 for major depressive disorder (MDD) and focal onset seizures (FOS).